Home
Pipeline
For Patients
Investors
Publications
Contact Us
Overview
Oral Lichen Planus (OLP)
Hemorrhagic Cystitis (HC)
Oral Graft versus Host Disease (GvHD)
Non-Muscle Invasive Bladder Cancer (NMIBC)
Corporate Overview
SEC Filings
Press Releases
Stock Quote
Events
Corporate Governance
FAQ’s
Investor Relations Contact
All of the below publications are in PDF format.
Enhancing Therapeutic Efficacy and Safety of Immune Checkpoint Inhibition for Bladder Cancer: A Comparative Analysis of Injectable vs. Intravesical Administration
Intravesical liposomal tacrolimus for hemorrhagic cystitis: a phase 2a multicenter dose‑escalation study
Haemorrhagic cystitis: a review of management strategies and emerging treatments
ncsd.org
A Message from the National Cancer Institute
Lower Urinary Tract Symptoms
Advances in Therapeutic Development for Radiation Cystitis
International Urology and Nephrology
Innovative Use of Intravesical Tacrolimus for Hemorrhagic Radiation Cystitis
Neurourology and Urodynamics
Intravesical Immune Suppression by Liposomal Tacrolimus in Cyclophosphamide-Induced Inflammatory Cystitis
The Journal of Urology
Intravesical Liposomal Tacrolimus Protects Against Radiation Cystitis Induced by 3-Beam Targeted Bladder Radiation
American Journal of Renal Physiology
Novel contrast mixture improves bladder wall contrast for visualizing bladder injury
F1000 Research
Recent Advances in Imaging and Understanding Interstitial Cystitis
